ArticleFrontiers in medicine2025
Risk of hematologic malignancies following herpes zoster after COVID-19: a global cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association Between Post-COVID-19 Herpes Zoster Reactivation and Peripheral Nervous System Disorders: Multinational Real-World Evidence from TriNetX.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Herpes zoster (HZ) has been reported as a potential post-viral complication in individuals recovering from COVID-19, possibly due to virus-induced immune dysregulation. We aimed to investigate whether post-COVID HZ is associated with an elevated risk of hematologic or infectious complications. Methods: We conducted a retrospective cohort study using the TriNetX global research network, which aggregates de-identified electronic health records from more than 140 healthcare institutions. Adults diagnosed with COVID-19 between January 2020 and January 2022 were stratified by the presence or absence of HZ within one year of infection and matched 1:1 by age, sex, and comorbidities. Outcomes including leukopenia, urinary tract infection, multiple myeloma, and acute leukemia were evaluated over a three-year follow-up using time-to-event and multivariable Cox regression analyses. Results: Individuals with post-COVID HZ had significantly higher risks of developing hematologic and infectious complications. Subgroup analyses identified older age, impaired kidney function, elevated inflammatory markers, and metabolic abnormalities as factors associated with greater risk. Discussion: These findings suggest that HZ following COVID-19 may serve as a clinical indicator of immune vulnerability and heightened susceptibility to hematologic and infectious disorders. Long-term monitoring may be warranted in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.